American Journal of Kidney Diseases最新文献

筛选
英文 中文
Nephrology Leadership Through Collaboration to Deliver on CKD Care 通过合作实现CKD护理的肾病学领导。
IF 8.2 1区 医学
American Journal of Kidney Diseases Pub Date : 2026-03-01 Epub Date: 2026-02-19 DOI: 10.1053/j.ajkd.2026.01.002
Jehan Zahid Bahrainwala , Jo-Anne L. Suffoletto , Brian M. Brady
{"title":"Nephrology Leadership Through Collaboration to Deliver on CKD Care","authors":"Jehan Zahid Bahrainwala , Jo-Anne L. Suffoletto , Brian M. Brady","doi":"10.1053/j.ajkd.2026.01.002","DOIUrl":"10.1053/j.ajkd.2026.01.002","url":null,"abstract":"","PeriodicalId":7419,"journal":{"name":"American Journal of Kidney Diseases","volume":"87 3","pages":"Pages 295-297"},"PeriodicalIF":8.2,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146775978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Blood Pressure–Lowering Agents for Kidney Transplant Recipients: Editorial Summary of a Cochrane Review 肾移植受者的降压药:Cochrane综述的编辑摘要。
IF 8.2 1区 医学
American Journal of Kidney Diseases Pub Date : 2026-02-01 Epub Date: 2025-12-04 DOI: 10.1053/j.ajkd.2025.07.022
Patrizia Natale , Suetonia C. Green , Jonathan C. Craig , Giovanni F.M. Strippoli
{"title":"Blood Pressure–Lowering Agents for Kidney Transplant Recipients: Editorial Summary of a Cochrane Review","authors":"Patrizia Natale , Suetonia C. Green , Jonathan C. Craig , Giovanni F.M. Strippoli","doi":"10.1053/j.ajkd.2025.07.022","DOIUrl":"10.1053/j.ajkd.2025.07.022","url":null,"abstract":"","PeriodicalId":7419,"journal":{"name":"American Journal of Kidney Diseases","volume":"87 2","pages":"Pages 270-272"},"PeriodicalIF":8.2,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145688972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
KDOQI US Commentary on the KDIGO 2025 Clinical Practice Guideline for the Management of Nephrotic Syndrome in Children KDOQI对KDIGO 2025儿童肾病综合征管理临床实践指南的评论
IF 8.2 1区 医学
American Journal of Kidney Diseases Pub Date : 2026-02-01 Epub Date: 2026-01-21 DOI: 10.1053/j.ajkd.2025.10.006
Chia-shi Wang , Rasheed Gbadegesin
{"title":"KDOQI US Commentary on the KDIGO 2025 Clinical Practice Guideline for the Management of Nephrotic Syndrome in Children","authors":"Chia-shi Wang ,&nbsp;Rasheed Gbadegesin","doi":"10.1053/j.ajkd.2025.10.006","DOIUrl":"10.1053/j.ajkd.2025.10.006","url":null,"abstract":"<div><div>The Kidney Disease Outcomes Quality Initiative (KDOQI) convened a work group to review the 2025 KDIGO (Kidney Disease: Improving Global Outcomes) Clinical Practice Guideline for the Management of Nephrotic Syndrome in Children. The KDOQI work group reviewed the KDIGO guideline statements and practice points and provided perspective for implementation within the context of clinical practice in the United States. The updated guidelines reflect contemporary US practice and offer highly relevant guidance that is harmonized with the International Pediatric Nephrology Association’s guidelines published in 2020 and 2022. A focus on close monitoring and characterization of the disease status for children with nephrotic syndrome remains central to treatment and management decisions, noting that the lack of insurance coverage for urine dipsticks in the United States is a significant barrier to optimal disease management. As more treatment options become available to children with nephrotic syndrome, the detailed practice points are a sound tool to help providers engage patients and their families in joint decision making. The clinical utility of the guidelines would be enhanced by inclusion of practice points on the incorporation of genetic testing results into treatment decisions, as well as factors to consider when treating and managing patients at high risk for progression to end-stage kidney disease—those with secondary steroid-resistant nephrotic syndrome and those with the chronic kidney disease high-risk <em>APOL1</em> genotype. The research needs detailed in the updated guidelines reflect the exciting direction of the practice landscape to provide patient-centered, precision-based care.</div></div>","PeriodicalId":7419,"journal":{"name":"American Journal of Kidney Diseases","volume":"87 2","pages":"Pages 141-152"},"PeriodicalIF":8.2,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146001700","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Chronic Pain in Hemodialysis: Beyond the Biochemical Paradigm 血液透析中的慢性疼痛:超越生化范式。
IF 8.2 1区 医学
American Journal of Kidney Diseases Pub Date : 2026-02-01 Epub Date: 2025-12-19 DOI: 10.1053/j.ajkd.2025.11.003
James O. Burton DM, MBChB , Katherine L. Hull MBChB
{"title":"Chronic Pain in Hemodialysis: Beyond the Biochemical Paradigm","authors":"James O. Burton DM, MBChB ,&nbsp;Katherine L. Hull MBChB","doi":"10.1053/j.ajkd.2025.11.003","DOIUrl":"10.1053/j.ajkd.2025.11.003","url":null,"abstract":"","PeriodicalId":7419,"journal":{"name":"American Journal of Kidney Diseases","volume":"87 2","pages":"Pages 156-158"},"PeriodicalIF":8.2,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145786361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Practical Primer on How to Detect and Treat Depression in CKD 如何检测和治疗慢性肾病抑郁症的实用入门。
IF 8.2 1区 医学
American Journal of Kidney Diseases Pub Date : 2026-02-01 Epub Date: 2025-11-13 DOI: 10.1053/j.ajkd.2025.07.020
L. Parker Gregg , Lynnel Goodman , Ella Q. Carroll , S. Susan Hedayati
{"title":"A Practical Primer on How to Detect and Treat Depression in CKD","authors":"L. Parker Gregg ,&nbsp;Lynnel Goodman ,&nbsp;Ella Q. Carroll ,&nbsp;S. Susan Hedayati","doi":"10.1053/j.ajkd.2025.07.020","DOIUrl":"10.1053/j.ajkd.2025.07.020","url":null,"abstract":"<div><div>The detection and management of depression have special considerations in people with kidney disease. Screening should be performed every 6-12 months using a self-reported questionnaire. Clinicians should rule out symptoms from medical conditions such as dialysis inadequacy or hypothyroidism and confirm the presence of sadness or anhedonia. Sertraline has shown limited efficacy and an increased risk for adverse effects such as gastrointestinal symptoms, so cautious, gradual dose titration is warranted. Cognitive behavioral therapy has potential benefit for depressive symptoms in people with kidney disease. Current trials are evaluating behavioral activation therapy. Physical activity has many benefits and likely improves depression.</div></div>","PeriodicalId":7419,"journal":{"name":"American Journal of Kidney Diseases","volume":"87 2","pages":"Pages 239-245"},"PeriodicalIF":8.2,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145525118","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Low-Flow Home Hemodialysis Technologies: The Key to Greener Dialysis? 低流量家庭血液透析技术:绿色透析的关键?
IF 8.2 1区 医学
American Journal of Kidney Diseases Pub Date : 2026-02-01 Epub Date: 2025-12-02 DOI: 10.1053/j.ajkd.2025.08.017
Elena Cuadrado-Payán MD, José Jesús Broseta PhD, Aleix Cases PhD
{"title":"Low-Flow Home Hemodialysis Technologies: The Key to Greener Dialysis?","authors":"Elena Cuadrado-Payán MD,&nbsp;José Jesús Broseta PhD,&nbsp;Aleix Cases PhD","doi":"10.1053/j.ajkd.2025.08.017","DOIUrl":"10.1053/j.ajkd.2025.08.017","url":null,"abstract":"","PeriodicalId":7419,"journal":{"name":"American Journal of Kidney Diseases","volume":"87 2","pages":"Page 284"},"PeriodicalIF":8.2,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145674415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
What is Medicare Advantage and Why is it the Most Important Contemporary Policy Affecting Kidney Disease? 什么是医疗保险优势,为什么它是影响肾脏疾病的最重要的当代政策?
IF 8.2 1区 医学
American Journal of Kidney Diseases Pub Date : 2026-02-01 Epub Date: 2025-11-12 DOI: 10.1053/j.ajkd.2025.07.019
Jillian S. Caldwell , Eugene Lin
{"title":"What is Medicare Advantage and Why is it the Most Important Contemporary Policy Affecting Kidney Disease?","authors":"Jillian S. Caldwell ,&nbsp;Eugene Lin","doi":"10.1053/j.ajkd.2025.07.019","DOIUrl":"10.1053/j.ajkd.2025.07.019","url":null,"abstract":"<div><div>Medicare Advantage (MA) enrollment among patients receiving dialysis has surged following the passage of the 21st Century Cures Act, which lifted prior restrictions on enrollment. As MA becomes the plurality payer for dialysis, understanding its implications for patients, providers, and policymakers is critical. MA offers out-of-pocket spending caps and additional services not covered under fee-for-service (FFS) Medicare. Some plans also prioritize care coordination, which may improve patient outcomes. However, concerns remain regarding limited provider networks, prior authorization barriers, and disparities in access to medications and transplants. The increasing shift to MA also challenges value-based care models, as most quality measures and payment models for patients receiving dialysis are limited to FFS Medicare. Although research examining the benefits and downsides of MA is paramount, a comparison of MA versus FFS Medicare is complicated by selection bias and incomplete or inaccessible data. To ensure that increasing enrollment into MA has not harmed patients, policymakers must enhance data fidelity and transparency, strengthen regulatory oversight, and align financial incentives across populations to safeguard access to high-quality care for patients receiving dialysis.</div></div>","PeriodicalId":7419,"journal":{"name":"American Journal of Kidney Diseases","volume":"87 2","pages":"Pages 260-269"},"PeriodicalIF":8.2,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145516259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Glucagon-like Peptide-1 Receptor Agonists and Risk of Major Adverse Cardiovascular Events in Patients With CKD 胰高血糖素样肽-1受体激动剂与CKD患者主要不良心血管事件的风险
IF 8.2 1区 医学
American Journal of Kidney Diseases Pub Date : 2026-02-01 Epub Date: 2025-11-12 DOI: 10.1053/j.ajkd.2025.09.010
Kevin Yau , Joel G. Ray , Nivethika Jeyakumar , Bin Luo , Sheikh Abdullah , Stephanie N. Dixon , Sara Wing , Kristin K. Clemens , Fabio Castrillon-Ramirez , Jacob A. Udell , Alejandro Meraz-Munoz , Ann Young , Ziv Harel , Jeffrey Perl , Lawrence A. Leiter , Amit X. Garg , David Z.I. Cherney , Ron Wald
{"title":"Glucagon-like Peptide-1 Receptor Agonists and Risk of Major Adverse Cardiovascular Events in Patients With CKD","authors":"Kevin Yau ,&nbsp;Joel G. Ray ,&nbsp;Nivethika Jeyakumar ,&nbsp;Bin Luo ,&nbsp;Sheikh Abdullah ,&nbsp;Stephanie N. Dixon ,&nbsp;Sara Wing ,&nbsp;Kristin K. Clemens ,&nbsp;Fabio Castrillon-Ramirez ,&nbsp;Jacob A. Udell ,&nbsp;Alejandro Meraz-Munoz ,&nbsp;Ann Young ,&nbsp;Ziv Harel ,&nbsp;Jeffrey Perl ,&nbsp;Lawrence A. Leiter ,&nbsp;Amit X. Garg ,&nbsp;David Z.I. Cherney ,&nbsp;Ron Wald","doi":"10.1053/j.ajkd.2025.09.010","DOIUrl":"10.1053/j.ajkd.2025.09.010","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Rationale &amp; Objective&lt;/h3&gt;&lt;div&gt;There are limited real-world data describing the cardiovascular benefits of glucagon-like peptide-1 receptor agonists (GLP1-RAs) across the spectrum of chronic kidney disease (CKD) severity. This study evaluated the association of GLP1-RAs with major adverse cardiovascular events (MACE) in comparison with dipeptidyl peptidase-4 (DPP-4) inhibitors in the setting of CKD.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Study Design&lt;/h3&gt;&lt;div&gt;Retrospective observational cohort study.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Setting &amp; Participants&lt;/h3&gt;&lt;div&gt;24,576 new users of GLP1-RA and 44,367 new users of DPP-4 inhibitors with estimated glomerular filtration rate (eGFR) &lt; 90 mL/min/1.73 m&lt;sup&gt;2&lt;/sup&gt; in Ontario, Canada.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Exposure&lt;/h3&gt;&lt;div&gt;New use of GLP1-RAs versus DPP-4 inhibitors.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Outcome&lt;/h3&gt;&lt;div&gt;The primary outcome was MACE, comprising nonfatal myocardial infarction, unstable angina, nonfatal ischemic stroke or transient ischemic attack, coronary revascularization, and cardiovascular death. Secondary outcomes included individual components of the composite outcome, hospitalization or emergency department visits for congestive heart failure, peripheral vascular disease revascularization, lower limb amputation, and all-cause mortality.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Analytical Approach&lt;/h3&gt;&lt;div&gt;Inverse probability of treatment weighting using propensity scores was used to minimize confounding. Multivariable Fine-Gray subdistribution hazard models stratified by eGFR subgroup were fit to evaluate the primary outcome.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Findings&lt;/h3&gt;&lt;div&gt;Mean age of study participants was 69 years, 50% were female, 92% had type 2 diabetes mellitus, 40% were taking a sodium/glucose cotransporter 2 (SGLT2) inhibitor, and 41% had CKD stages 3-5. MACE occurred among 1,296 (31.6 per 1,000 person-years) GLP1-RA users versus 1,374 (36.5 per 1,000 person-years) DPP-4 inhibitor users (subdistribution hazard ratio [SHR], 0.88 [95% CI, 0.80-0.97]). The lower rate of MACE among GLP1-RA users was largely related to a lower rate of cardiovascular death (SHR, 0.72 [95% CI, 0.62-0.85]). In subgroup analyses, there was no effect modification between the association of GLP1-RA initiation and lower rates of MACE by CKD stages, degree of albuminuria, or concomitant use of SGLT2 inhibitors.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Limitations&lt;/h3&gt;&lt;div&gt;Retrospective design. A substantial amount of missing information on albuminuria.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusions&lt;/h3&gt;&lt;div&gt;In a population-based study of individuals across the spectrum of kidney disease, GLP1-RA initiation was associated with a lower rate of MACE than initiation of DPP-4 inhibitors.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Plain-Language Summary&lt;/h3&gt;&lt;div&gt;A class of medications called glucagon-like peptide-1 receptor agonists (GLP1-RA) is now used for the treatment of diabetes. This study explored the association of GLP1-RA administration with cardiac health in people with kidney disease compared with another common cl","PeriodicalId":7419,"journal":{"name":"American Journal of Kidney Diseases","volume":"87 2","pages":"Pages 211-229.e1"},"PeriodicalIF":8.2,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145516256","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
GFR Measured With Computerized Tomography Urography in Healthy Individuals and Patients With CKD 用计算机断层尿路造影测量健康个体和CKD患者的GFR。
IF 8.2 1区 医学
American Journal of Kidney Diseases Pub Date : 2026-02-01 Epub Date: 2025-11-12 DOI: 10.1053/j.ajkd.2025.07.018
Thomas Stehlé , Sarah Najhi , Félix Wei , Florence Canouï-Poitrine , Séverine Brabant , Alain Luciani , Philippe Grimbert , Dominique Prié , Cécile-Maud Champy , Edouard Reizine , Marie Matignon , Tiphaine Pelegrin , Soraya Fellahi , Paul Brasseur , Alexandre Ingels , Frédéric Pigneur
{"title":"GFR Measured With Computerized Tomography Urography in Healthy Individuals and Patients With CKD","authors":"Thomas Stehlé ,&nbsp;Sarah Najhi ,&nbsp;Félix Wei ,&nbsp;Florence Canouï-Poitrine ,&nbsp;Séverine Brabant ,&nbsp;Alain Luciani ,&nbsp;Philippe Grimbert ,&nbsp;Dominique Prié ,&nbsp;Cécile-Maud Champy ,&nbsp;Edouard Reizine ,&nbsp;Marie Matignon ,&nbsp;Tiphaine Pelegrin ,&nbsp;Soraya Fellahi ,&nbsp;Paul Brasseur ,&nbsp;Alexandre Ingels ,&nbsp;Frédéric Pigneur","doi":"10.1053/j.ajkd.2025.07.018","DOIUrl":"10.1053/j.ajkd.2025.07.018","url":null,"abstract":"","PeriodicalId":7419,"journal":{"name":"American Journal of Kidney Diseases","volume":"87 2","pages":"Pages 234-238"},"PeriodicalIF":8.2,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145516286","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Health-Related Quality of Life After Living Kidney Donation: Insights From a Contemporary Meta-Analysis 活体肾脏捐献后健康相关生活质量:来自当代荟萃分析的见解
IF 8.2 1区 医学
American Journal of Kidney Diseases Pub Date : 2026-02-01 Epub Date: 2025-12-20 DOI: 10.1053/j.ajkd.2025.11.002
Neetika Garg , Carrie Thiessen , Didier A. Mandelbrot
{"title":"Health-Related Quality of Life After Living Kidney Donation: Insights From a Contemporary Meta-Analysis","authors":"Neetika Garg ,&nbsp;Carrie Thiessen ,&nbsp;Didier A. Mandelbrot","doi":"10.1053/j.ajkd.2025.11.002","DOIUrl":"10.1053/j.ajkd.2025.11.002","url":null,"abstract":"","PeriodicalId":7419,"journal":{"name":"American Journal of Kidney Diseases","volume":"87 2","pages":"Pages 153-155"},"PeriodicalIF":8.2,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145786058","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书